News Release

Printer Friendly VersionView printer-friendly version << Back



AcelRx Pharmaceuticals Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting

Data from Sublingual Sufentanil Development Program Highlights Onset of Analgesia, Safety and Effect of Gender on Analgesic Response

REDWOOD CITY, Calif., Oct. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the upcoming American Society of Anesthesiologists (ASA 2014) meeting October 11th to October 15th, 2014 at the Ernest N. Morial Convention Center in New Orleans, LA.  The annual ASA meeting is the premier anesthesiology educational event in the world with more than 15,000 attendees from over 90 countries expected to attend.   Pamela Palmer, M.D. Ph.D. will present safety and efficacy data from the phase 3 trials evaluating the Zalviso™ sufentanil sublingual tablet system, under FDA evaluation for the potential treatment of moderate-to-severe acute pain in the hospital setting.  Results from a phase 2, dose-finding study of a second sublingual sufentanil product candidate will also be presented.      

Details on the presentation times are as follows:

Saturday, October 11, 2014 – Moderated Poster Session, Hall B1, Area E, Poster A1225, Monitor 2 – Presentation time 11:30-12:00 Noon (local time)

Authors:

Pamela Palmer, MD, PhD, Harold Minkowitz, MD, Tong-Joo Gan, MD 



Title:

A PHASE 3 META-ANALYSIS OF OPIOID ADVERSE EVENTS WITH ZALVISO (SUFENTANIL SUBLINGUAL TABLET SYSTEM) COMPARED TO IV PATIENT-CONTROLLED ANALGESIA WITH MORPHINE

Saturday, October 11, 2014 – Moderated Poster Session, Hall B1, Area E, Poster A1300, Monitor 1 – Presentation time 2:00-2:30pm (local time)

Authors:

Pamela P. Palmer, MD, PhD, Neil K. Singla, MD, Derek D. Muse, MD, Mark A. Evashenk, BS 



Title:

SUFENTANIL SUBLINGUAL MICROTABLETS FOR ACUTE PAIN FOLLOWING BUNIONECTOMY: EFFECT OF GENDER ON ANALGESIC RESPONSE

Monday, October 13, 2014 – Moderated Poster Session, Hall B1, Area B, Poster A3302, Monitor 2 – Presentation time 1:00-1:30pm (local time)

Authors:

Pamela P. Palmer, MD, PhD, Harold S. Minkowitz, MD, Tong-Joo Gan, MD 



Title:

A PHASE 3 META-ANALYSIS OF ONSET OF ANALGESIA FOR ZALVISO (SUFENTANIL SUBLINGUAL TABLET SYSTEM) COMPARED TO IV PATIENT-CONTROLLED ANALGESIA WITH MORPHINE

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, Zalviso, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting and on July 25th, received a Complete Response Letter from the FDA.  AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, by the end of 2014. The Company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

AcelRx logo.

Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO

SOURCE AcelRx Pharmaceuticals, Inc.

Timothy E. Morris, Chief Financial Officer, 650.216.3511, tmorris@acelrx.com, Brian Korb, The Trout Group LLC, 646.378.2923, bkorb@troutgroup.com